Publicaciones en las que colabora con Susana Roselló (14)

2023

  1. "Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction"

    Journal of experimental & clinical cancer research : CR, Vol. 42, Núm. 1, pp. 8

2022

  1. Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma

    British Journal of Cancer, Vol. 127, Núm. 12, pp. 2198-2206

2021

  1. Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study

    British Journal of Cancer, Vol. 125, Núm. 9, pp. 1261-1269

2020

  1. Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer

    ESMO Open, Vol. 5, Núm. 5

  2. EPDR1 up-regulation in human colorectal cancer is related to staging and favours cell proliferation and invasiveness

    Scientific Reports, Vol. 10, Núm. 1

  3. The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target

    Cancer Treatment Reviews, Vol. 86

2019

  1. Nrf2 through RPs6 activation is related to anti-HER2 drug resistance in HER2-amplified gastric cancer

    Clinical Cancer Research, Vol. 25, Núm. 5, pp. 1639-1649

  2. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 30, Núm. 11, pp. 1804-1812

  3. Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma

    Annals of Oncology, Vol. 30, Núm. 8, pp. 1254-1264

2018

  1. A multi-omic analysis for prospective patient stratification in localised colorectal cancer (CRC)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii717

  2. NRF2 activation via PI3K/AKT/mTOR/RPS6 causes resistance to anti-HER2 agents among HER2 amplified gastric cancer

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii224

  3. RPS6 through the activation of NRF2 causes resistance to antiHER2 drugs in HER2 amplified gastric cancer (GC) models

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. vi31-vi32

2016

  1. Epigenetic changes in localized gastric cancer: The role of RUNX3 in tumor progression and the immune microenvironment

    Oncotarget, Vol. 7, Núm. 39, pp. 63424-63436

2015

  1. EGF-Induced acetylation of heterogeneous nuclear ribonucleoproteins is dependent on KRAS mutational status in colorectal cancer cells

    PLoS ONE, Vol. 10, Núm. 6